Cited by 498Cannabis and Cannabinoid ResearchAdenosine and Purinergic SignalingInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Open access

Carrier, Erica J., Auchampach, John A., Hillard, Cecilia J.·2006·Proceedings of the National Academy of Sciences

Open this paper in CoChat — free account Open PDF

Abstract

The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; although some effects of THC are mediated by the CB2 receptor, CB2 binds CBD weakly. In examining the effects of THC and CBD on microglial proliferation, we found that these compounds potently inhibit [3H]thymidine incorporation into a murine microglial cell line with no effect on cell cycle. Treatment with THC and CBD decreased [3H]thymidine uptake into microglia, with IC50 values that match inhibition of [3H]thymidine incorporation into DNA. CBD and, less potently, THC decreased uptake of [3H]adenosine to a similar extent as [3H]thymidine in both murine microglia and RAW264.7 macrophages. Binding studies confirm that CBD binds to the equilibrative nucleoside transporter 1 with a Ki < 250 nM. Because adenosine agonists have antiinflammatory effects, and because uptake of adenosine is a primary mechanism of terminating adenosine signaling, we tested the hypothesis that CBD is immunosuppressive because it enhances endogenous adenosine signaling. In vivo treatment with a low dose of CBD decreases TNFalpha production in lipopolysaccharide-treated mice; this effect is reversed with an A2A adenosine receptor antagonist and abolished in A2A receptor knockout mice. These studies demonstrate that CBD has the ability to enhance adenosine signaling through inhibition of uptake and provide a non-cannabinoid receptor mechanism by which CBD can decrease inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0511232103

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Reactive microgliosis
Streit, W. J., Walter, S. A., & Pennell, N. A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00069-0 · Cited by 1,096
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 546
The cannabinoid system and immune modulation
Klein, T., Newton, C. A., Larsen, K. A., Lu, L. D., Perkins, I., Nong, L., & Friedman, H. P. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 533
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 530

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 7

R. K. Razdan Pharmacol. Rev 38, 75–149 (1986).
R. G. Pertwee Cannabinoids, ed V. Di Marzo (Kluwer Academic/Plenum Publishers, New York), pp. 32–83 (2004).
A. C. Howlett, J. M. Qualy, L. L. Khachatrian Mol. Pharmacol 29, 307–313 (1986).
B. Desoize, C. Leger, J. C. Jardillier, G. Nahas Adv. Biosci 22–23, 145–159 (1978).
B. Desoize, C. Leger, G. Nahas C. R. Hebd. Seances Acad. Sci. D 287, 1441–1444 (1978).
P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, H. Calvert, D. R. Newell, N. J. Curtin Clin. Cancer Res 7, 2105–2113 (2001).
A. S. Gordon, L. Nagy, D. Mochly-Rosen, I. Diamond Biochem. Soc. Symp 56, 117–136 (1990).

Sorted by citations

Items 201–300 of 498

Role of the purinergic signaling in epilepsy
Cieślak, M., Wojtczak, A., & Komoszyński, M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.09.018 · Cited by 47
Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles
Sionov, R. V., & Steinberg, D. (2022) · Biomedicines · doi:10.3390/biomedicines10030631 · Cited by 51
Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs
Polidoro, D. N., Temmerman, R., Devreese, M., Charalambous, M., Ham, L. V., Cornelis, I., Broeckx, B. J. G., Mandigers, P. J. J., Fischer, A., Storch, J., et al. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.899940 · Cited by 50
Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)
Nazario, L. R., Antonioli, R., Capiotti, K. M., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., Bonan, C. D., & da Silva, R. S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.06.008 · Cited by 50
Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats
Mijangos-Moreno, S., Poot-Aké, A., Arankowsky‐Sandoval, G., & Murillo‐Rodríguez, E. (2014) · Neuroscience Research · doi:10.1016/j.neures.2014.04.006 · Cited by 49
Evaluation of pharmacokinetics and acute anti‐inflammatory potential of two oral cannabidiol preparations in healthy adults
Hobbs, J. M., Vazquez, A. R., Remijan, N. D., Trotter, R. E., Vincent, G. T., Freedman, K. E., Wei, Y., Woelfel, K. A., Arnold, O. R., Wolfe, L. M., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6651 · Cited by 46
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Manzoni, O. J., Manduca, A., & Trezza, V. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.005 · Cited by 45
Cannabidiol treatment ameliorates ischemia/reperfusion renal injury in rats
Fouad, A. A., Al-Mulhim, A. S., & Jresat, I. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.07.030 · Cited by 45
The Non-Psychoactive Plant Cannabinoid, Cannabidiol Affects Cholesterol Metabolism-Related Genes in Microglial Cells
Rimmerman, N., Juknat, A., Kozela, E., Levy, R., Bradshaw, H. B., & Vogel, Z. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9692-3 · Cited by 45
Delta9‐tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature
Fowler, C. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.84 · Cited by 44
MK-801-induced deficits in social recognition in rats
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Kikuchi, T., Stott, C. G., & Riedel, G. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000178 · Cited by 49
The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products
Li, J., Carvajal, R., Bruner, L. H., & Kaminski, N. E. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112600 · Cited by 49
Adenosine mediates transforming growth factor‐beta 1 release in kidney glomeruli of diabetic rats
Roa, H., Gajardo, C., Troncoso, E., Fuentealba, V., Escudero, C., Yáñez, A. J., Sobrevía, L., Pastor‐Anglada, M., Quezada, C., & Martín, R. S. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.09.003 · Cited by 44
DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor
Silva, R. L., Silveira, G. T., Wanderlei, C. W., Cecílio, N. T., Maganin, A. G. M., Franchin, M., Marques, L. M. M., Lopes, N. P., Crippa, J. A., Guimarães, F. S., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.02.011 · Cited by 43
Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration
Silveira, J. W. S., Issy, A. C., Castania, V., Salmón, C. E. G., Nogueira‐Barbosa, M. H., Guimarães, F. S., Defino, H. L. A., & Bel, E. A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113161 · Cited by 42
Adenosine A2B receptor-mediated VEGF induction promotes diabetic glomerulopathy
Cárdenas, A., Toledo, C., Oyarzun, C. E., Sepúlveda, A., Quezada, C., Guillén‐Gómez, E., Encarnación, M. M. D., Pastor‐Anglada, M., & Martín, R. S. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.143 · Cited by 42
Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury
Soares, R. Z., Vuolo, F. S., Dall’Igna, D. M., Michels, M., Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., & Dal‐Pizzol, F. (2015) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20150064 · Cited by 40
Cannabis and Athletic Performance
Burr, J. F., Cheung, C. P., Kasper, A. M., Gillham, S. H., & Close, G. L. (2021) · Sports Medicine · doi:10.1007/s40279-021-01505-x · Cited by 43
Endocannabinoid System in the Airways
Bozkurt, T. E. (2019) · Molecules · doi:10.3390/molecules24244626 · Cited by 41
Meroterpenoids with diverse structures and anti-inflammatory activities from Rhododendron anthopogonoides
Shi, Q., Li, T.-T., Wu, Y., Sun, X.-Y., Lei, C., Li, J.-Y., & Hou, A. (2020) · Phytochemistry · doi:10.1016/j.phytochem.2020.112524 · Cited by 40
Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction
Olière, S., Joliette-Riopel, A., Potvin, S., & Jutras‐Aswad, D. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00109 · Cited by 41
A time‐dependent contribution of hippocampal CB1, CB2 and PPARγ receptors to cannabidiol‐induced disruption of fear memory consolidation
Raymundi, A. M., da Silva, T. R., Zampronio, A. R., Guimarães, F. S., Bertoglio, L. J., & Stern, C. A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14895 · Cited by 39
Cannabidiol and Neurodevelopmental Disorders in Children
Cheung, K. A. K., Mitchell, M. D., & Heussler, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.643442 · Cited by 39
Therapeutic Time Window of Cannabidiol Treatment on Delayed Ischemic Damage via High-Mobility Group Box1-Inhibiting Mechanism
Hayakawa, K., Irie, K., Sano, K., Watanabe, T., Higuchi, S., Enoki, M., Nakano, T., Harada, K., Ishikane, S., Ikeda, T., et al. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1538 · Cited by 42
Non-psychotropic analgesic drugs from the endocannabinoid system: “Magic bullet” or “multiple-target” strategies?
Starowicz, K., & Marzo, V. D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.075 · Cited by 39
Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal
Navarrete, F., Aracil-Fernández, A., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14226 · Cited by 38
Cannabis Sativa Revisited—Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis
Dinu, A. R., Rogobete, A. F., Bratu, T., Popovici, S. E., Bedreag, O. H., Păpurică, M., Bratu, T., & Săndesc, D. (2020) · Cells · doi:10.3390/cells9020307 · Cited by 38
A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers
Perkins, D., Butler, J., Ong, K., Nguyen, T., Cox, S. W., Francis, B., McIntosh, M. P., & Lilley, B. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00624-6 · Cited by 38
Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
Fouad, A. A., & Jresat, I. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.08.048 · Cited by 38
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
Buchtová, T., Lukáč, D., Škrott, Z., Chromá, K., Bártek, J., & Mistrík, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032885 · Cited by 38
Cannabinoids and the Microbiota–Gut–Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders
Karoly, H. C., Mueller, R. L., Bidwell, L. C., & Hutchison, K. E. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14256 · Cited by 37
Cannabidiol modulation of hippocampal glutamate in early psychosis
O’Neill, A., Annibale, L., Blest‐Hopley, G., Wilson, R. P., Giampietro, V., & Bhattacharyya, S. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211001107 · Cited by 37
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
Liou, G. I. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i1.12 · Cited by 37
Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence
Ladha, K. S., Ajrawat, P., Yang, Y., & Clarke, H. A. (2020) · Molecules · doi:10.3390/molecules25184042 · Cited by 36
Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells
Juknat, A., Rimmerman, N., Levy, R., Vogel, Z., & Kozela, E. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.12.002 · Cited by 35
Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
Calapai, G., Mannucci, C., Chinou, İ., Cardia, L., Calapai, F., Sorbara, E. E., Firenzuoli, B., Ricca, V., Gensini, G. F., & Firenzuoli, F. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2509129 · Cited by 36
Cannabidiol in sport: Ergogenic or else?
Gamelin, F.-X., Cuvelier, G., Mendes, A., Aucouturier, J., Berthoin, S., Marzo, V. D., & Heyman, E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104764 · Cited by 38
Therapeutic potential of cannabinoids in combination cancer therapy
Malhotra, P., Casari, I., & Falasca, M. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100774 · Cited by 33
Cannabinoids: a class of unique natural products with unique pharmacology
Piscitelli, F., & Marzo, V. D. (2021) · RENDICONTI LINCEI · doi:10.1007/s12210-020-00966-y · Cited by 33
Marijuana Use and Brain Immune Mechanisms
Cabral, G. A., & Jamerson, M. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00008-7 · Cited by 34
Cannabidiol promotes adipogenesis of human and mouse mesenchymal stem cells via PPARγ by inducing lipogenesis but not lipolysis
Chang, R. C.-A., Thangavelu, C. S., Joloya, E. M., Kuo, Y., Li, Z., & Blumberg, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114910 · Cited by 34
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes
Blevins, L. K., Bach, A. P., Crawford, R. B., Zhou, J., Henriquez, J. E., Rizzo, M. D., Sermet, S., Khan, D. M. I. O., Turner, H. C., Small-Howard, A. L., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113458 · Cited by 34
Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities
Kaur, T., Weadick, B., Mace, T. A., Desai, K., Odom, H., & Govindarajan, R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108300 · Cited by 34
Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus
Patel, D. C., Wallis, G. J., Fujinami, R. S., Wilcox, K. S., & Smith, M. D. (2019) · Epilepsia Open · doi:10.1002/epi4.12351 · Cited by 32
Use of cannabis in the treatment of animals: a systematic review of randomized clinical trials
Lima, T. D. M., Santiago, N. R., Alves, E. C. R., Chaves, D. S. D. A., & Visacri, M. B. (2022) · Animal Health Research Reviews · doi:10.1017/s1466252321000189 · Cited by 31
Single and combined effects of plant‐derived and synthetic cannabinoids on cognition and cannabinoid‐associated withdrawal signs in mice
Myers, A. M., Siegele, P. B., Foss, J. D., Tuma, R. F., & Ward, S. J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14147 · Cited by 31
Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs
Jacobson, K. A., & Reitman, M. L. (2020) · Cells · doi:10.3390/cells9040956 · Cited by 31
Cannabidiol in epilepsy: The indications and beyond
Ryan, M. A. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.11.317 · Cited by 33
Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy
Kretschmar, C., Oyarzun, C. E., Villablanca, C., Jaramillo, C., Alarcón, S., Perez, G., Encarnación, M. M. D., Pastor‐Anglada, M., Garrido, W., Quezada, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147430 · Cited by 30
Cannabidiol Induces Cytotoxicity and Cell Death via Apoptotic Pathway in Cancer Cell Lines
ChoiPark, W.-H.-D., Baek, S., Chu, J., Kang, M.-H., & Mi, Y.-J. (2008) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2008.16.2.087 · Cited by 29
Barriers to the wider adoption of medicinal Cannabis
Alexander, S. P. H. (2020) · British Journal of Pain · doi:10.1177/2049463720922884 · Cited by 28
Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies
Wang, F., & Multhoff, G. (2021) · Biomolecules · doi:10.3390/biom11040582 · Cited by 28
Development of cannabidiol full-spectrum oil/2,6-di-O-methyl-β-cyclodextrin inclusion complex with enhanced water solubility, bioactivity, and thermal stability
Li, H., Zhao, Q., Chang, S., Chang, T., Tan, M., & Zhao, B. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.118318 · Cited by 28
Cannabidiol administration into the bed nucleus of the stria terminalis alters cardiovascular responses induced by acute restraint stress through 5-HT1A receptor
Gomes, F. V., Alves, F. H. F., Guimarães, F. S., Correa, F. M. A., Resstel, L. B. M., & Crestani, C. C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.09.007 · Cited by 27
Elevated Pressure Changes the Purinergic System of Microglial Cells
Rodrigues‐Neves, A. C., Aires, I. D., Vindeirinho, J., Boia, R., Madeira, M. H., Gonçalves, F. Q., Cunha, R. A., Santos, P. F., Ambrósio, A. F., & Santiago, A. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00016 · Cited by 27
Behavioral and Molecular Effects Induced by Cannabidiol and Valproate Administration in the GASH/Sal Model of Acute Audiogenic Seizures
Cabral-Pereira, G., Sánchez-Benito, D., Díaz-Rodríguez, S. M., Gonçalves-Sánchez, J., Sancho, C., Castellano, O., Muñoz, L. J., López, D. E., & Gómez‐Nieto, R. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.612624 · Cited by 27
Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription
DeMarino, C., Cowen, M., Khatkar, P., Cotto, B., Branscome, H., Kim, Y., Sharif, S. A., Agbottah, E. T., Zhou, W., Costiniuk, C. T., et al. (2022) · Cells · doi:10.3390/cells11040723 · Cited by 27
Cannabidiol markedly alleviates skin and liver fibrosis
del Río, C., Ruíz-Pino, F., Prados, M. E., Fiebich, B. L., Tena‐Sempere, M., & Muñóz, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981817 · Cited by 28
Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test
Sartim, A. G., Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118784877 · Cited by 29
The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015
Farkas, S., Nagy, K., Jia, Z., Harkany, T., Palkovits, M., Donohou, S. R., Pike, V. W., Halldin, C., Máthé, D., Csiba, L., et al. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.02.012 · Cited by 26
Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities
Upadhya, D., de Castro, O. W., Upadhya, R., & Shetty, A. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0898-y · Cited by 26
A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
Cross, J. H., & Cock, H. R. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107861 · Cited by 26
Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine
Greco, R., Francavilla, M., Demartini, C., Zanaboni, A. M., Sodergren, M. H., Facchetti, S., Pacchetti, B., Palmisani, M., Franco, V., & Tassorelli, C. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01589-y · Cited by 26
Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats
Murillo‐Rodríguez, E., Arankowsky‐Sandoval, G., Rocha, N., Peniche-Amante, R., Veras, A. B., Machado, S. E. D. C., & Budde, H. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2565-0 · Cited by 26
Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury
Kwiatkoski, M., Guimarães, F. S., & Bel, E. A. D. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9273-8 · Cited by 25
Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice
Han, X., Song, X., Song, D., Xie, G., Guo, H., Wu, N., & Li, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06132-6 · Cited by 26
A Metabolomic Approach to the Pathogenesis of Ventilator-induced Lung Injury
Izquierdo-García, J. L., Naz, S., Nín, N., Rojas, Y., Erazo, M., Martínez‐Caro, L., Garcı́a, A., de Paula, M., Fernández-Segoviano, P., Casals, C., et al. (2013) · Anesthesiology · doi:10.1097/aln.0000000000000074 · Cited by 24
Design and application of locally delivered agonists of the adenosine A2Areceptor
Mantell, S. J., Jones, R., & Trevethick, M. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.57 · Cited by 24
Antiseizure effects of the cannabinoids in the amygdala‐kindling model
Fallah, M. S., Dlugosz, L., Scott, B. W., Thompson, M. D., & Burnham, W. M. (2021) · Epilepsia · doi:10.1111/epi.16973 · Cited by 25
Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry
Bellocchio, L., Patano, A., Inchingolo, A. D., Inchingolo, F., Dipalma, G., Isacco, C. G., de Ruvo, E., Rapone, B., Mancini, A., Lorusso, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119693 · Cited by 29
Protective effect of cannabidiol against cadmium hepatotoxicity in rats
Fouad, A. A., Al-Mulhim, A. S., & Gomaa, W. M. (2013) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2013.07.001 · Cited by 23
The Potential for Clinical Use of Cannabinoids in Treatment of Cardiovascular Diseases
Durst, R. Y., & Lotan, C. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00233.x · Cited by 23
Global Trends in Cannabis and Cannabidiol Research from the Year 1940 to 2019
Liu, J., Chen, H., Newmaster, S. G., Wang, S., & Liu, C. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200601152118 · Cited by 22
Molecular Mechanisms Through Which Cannabidiol May Affect Skeletal Muscle Metabolism, Inflammation, Tissue Regeneration, and Anabolism: A Narrative Review
Schouten, M., Dalle, S., & Koppo, K. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0220 · Cited by 22
Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children: Current State of Research
Evans, V., DeMarse, T. B., Febo, M., Johnson, C. R., Carney, P. R., & Anderson, C. L. (2017) · Journal of Pediatric Neurology · doi:10.1055/s-0037-1598109 · Cited by 22
Equilibrative Nucleoside Transporters-1 Inhibitors Act as Anti-epileptic Agents by Inhibiting Glutamatergic Transmission
Ho, S., Chen, I., Chang, K., Lin, H.-R., Tsai, C., Lin, C., & Liou, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.610898 · Cited by 22
Cannabidiol Signaling in the Eye and Its Potential as an Ocular Therapeutic Agent
Aebersold, A. S., Duff, M. B., Sloan, L. J., & Song, Z.-H. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000371 · Cited by 21
Effects of CA1 glutamatergic systems upon memory impairments in cholestatic rats
Hosseini, N., Nasehi, M., Radahmadi, M., & Zarrindast, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.018 · Cited by 21
Prior Cannabis Use Is Associated with Outcome after Intracerebral Hemorrhage
Napoli, M. D., Zha, A. M., Godoy, D. A., Masotti, L., Schreuder, F. H. B. M., Popa‐Wagner, A., Behrouz, R., & from the MNEMONICH Registry (2016) · Cerebrovascular Diseases · doi:10.1159/000443532 · Cited by 21
The endocannabinoid system, a novel and key participant in acupuncture’s multiple beneficial effects
Hu, B., Bai, F., Xiong, L., & Wang, Q. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.006 · Cited by 22
Cannabinoids
McCarberg, B. H. (2007) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v21n03_04 · Cited by 21
Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex
Jovel, C. A. E., Riveros, S., Almeida, C. E. B., Salazar, M. R., Inga, L. C., & Guío, L. (2023) · Seizure · doi:10.1016/j.seizure.2023.09.015 · Cited by 20
Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)
van Diepen, H. C., Schlicker, E., & Michel, M. C. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0327-2 · Cited by 20
Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101
Stollenwerk, T. M., Pollock, S., & Hillard, C. J. (2021) · Molecules · doi:10.3390/molecules26175354 · Cited by 19
Self-citation
A critical review of cannabis in medicine and dentistry: A look back and the path forward
Abidi, A. H., Alghamdi, S. S., & Derefinko, K. J. (2022) · Clinical and Experimental Dental Research · doi:10.1002/cre2.564 · Cited by 22
Chronic Pain and Cannabidiol in Animal Models: Behavioral Pharmacology and Future Perspectives
Silva-Cardoso, G. K., & Leite‐Panissi, C. R. A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0096 · Cited by 22
Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence
Zavala‐Tecuapetla, C., Luna‐Munguía, H., López‐Meraz, M. L., & Cuéllar‐Herrera, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416181 · Cited by 19
Dietary Cannabidiol Activates PKA/AMPK Signaling and Attenuates Chronic Inflammation and Leaky Gut in DSS‐Induced Colitis Mice
Sun, Q., Iniguez, A. B., Tian, Q., Du, ‬., & Zhu, M. J. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300446 · Cited by 19
Cannabidiol and Other Cannabinoids in Demyelinating Diseases
Navarrete, C. M., García‐Martín, A., Rolland, A. P., DeMesa, J., & Muñóz, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062992 · Cited by 20
Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target
Cavalheiro, E. K. F. F., Costa, A. B., Salla, D. H., da Silva, M. R., Mendes, T. F., da Silva, L. E., Turatti, C. D. R., de Bitencourt, R. M., & Rezin, G. T. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0016 · Cited by 22
Cannabidiol (CBD) and cognition in epilepsy
Gaston, T. E., Martin, R. C., & Szaflarski, J. P. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108316 · Cited by 21
Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence
Wright, S. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0003-4 · Cited by 19
Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development
Hau, R. K., Wright, S. H., & Cherrington, N. J. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2984 · Cited by 18
A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders
Omotayo, O. P., Lemmer, Y., & Mason, S. (2024) · Journal of Cannabis Research · doi:10.1186/s42238-024-00222-2 · Cited by 21
Role of adenosine in diabetic retinopathy
Liou, G. I., Ahmad, S., Naime, M., Fatteh, N., & Ibrahim, A. S. (2011) · Journal of ocular biology, diseases, and informatics · doi:10.1007/s12177-011-9067-5 · Cited by 18
A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development
Samanta, D. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108577 · Cited by 19
Reprint of “Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)”
Nazario, L. R., Antonioli, R., Capiotti, K. M., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., Bonan, C. D., & da Silva, R. S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.11.002 · Cited by 18
Alkylindole-sensitive receptors modulate microglial cell migration and proliferation
Fung, S., Cherry, A. E., Xu, C., & Stella, N. (2015) · Glia · doi:10.1002/glia.22845 · Cited by 17
“Recreational” Drug Abuse Associated with Failure to Mount a Proper Antibody Response after a Generalised Orthopoxvirus Infection
Huemer, H. P., Himmelreich, A., HÖNLINGER, B., Pavlic, M., Eisendle, K., Höpfl, R. M., Rabl, W., & Czerny, C. (2007) · Infection · doi:10.1007/s15010-007-6194-9 · Cited by 17
A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021
Liu, L., Liu, J., Zhao, M., Cai, M., Lei, F., Zeng, X., & Zhu, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.969883 · Cited by 17

Authors: Carrier, E. J., Auchampach, J. A., & Hillard, C. J.
Affiliations: Medical College of Wisconsin (US)
ORCID: Carrier, Erica J.
Auchampach, John A.
Hillard, Cecilia J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2006-05-16
Volume: 103
Issue: 20
Pages: 7895-7900
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0511232103
OpenAlex: W2067960394
Cited by: 497
References: 39
Citations by year: 2026: 20 · 2025: 30 · 2024: 29 · 2023: 33 · 2022: 40 · 2021: 33 · 2020: 40 · 2019: 32 · 2018: 19 · 2017: 25 · 2016: 20 · 2015: 19 · 2014: 11 · 2013: 20 · 2012: 24
FWCI: 14.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Heart, Lung, and Blood Institute (HL 077707, R01HL077707)
National Institute on Drug Abuse (R01DA009155, DA 16967, DA09155, R01DA016967)
National Institute of Neurological Disorders and Stroke (NS041314, R01NS041314)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: cannabidiol, delta-9-tetrahydrocannabinol, equilibrative nucleoside transporter 1, adenosine uptake, adenosine signaling, adenosine A2A receptor, microglial proliferation, macrophages, TNF-α, lipopolysaccharide-induced inflammation, anti-inflammatory activity
MeSH terms: Rimonabant, Adenosine, Animals, Camphanes, Cannabidiol, Cell Line, DNA, Immunosuppression Therapy, Lipopolysaccharides, Male, Mice, Inbred C57BL, Piperidines, Psychotropic Drugs, Pyrazoles, Dronabinol, Thymidine, Tumor Necrosis Factor-alpha, Microglia, Nucleoside Transport Proteins, Equilibrative Nucleoside Transporter 1, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks